More Exemption to Pharma Companies for R&D (India)
This article was originally published in PharmAsia News
Ram Vilas Paswan, India's Union Chemicals and Fertilizer Minister, announced that the government is committed to giving the country's pharmaceutical companies up to a 150 percent margin for research and development. Paswan hopes doing so will encourage drug-makers to further lower the prices on essential medications. At the same time, Paswan said the current price controls instituted by the country are not enough. He turned a deaf ear to the industry's argument that the prices for many drugs in India are much lower than most countries. According to Paswan, drugs must be less expensive in India because 80 percent of the country's population must pay for medications themselves. To further help the situation, the government is also planning to introduce health insurance for many of India's poorest citizens. (Click here for more
You may also be interested in...
The efforts to upgrade FDA’s information technology infrastructure may be opening up into an opportunity to reinvent its processes for regulatory decision making.
FDA should have all coronavirus vaccines evaluated by Vaccines and Related Biological Products Advisory Committee before approval, Democratic senators and representatives say; House subcommittee also wants FDA to require 30,000 participants in Phase III trials.
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.